{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:14:23Z","timestamp":1792005263530,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03055-w","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:21:04Z","timestamp":1733372464000},"page":"830-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data"],"prefix":"10.1007","volume":"42","author":[{"given":"Corinne","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-6508","authenticated-orcid":false,"given":"Lydia Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2988-5684","authenticated-orcid":false,"given":"Kristi K.","family":"DiRocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-7673","authenticated-orcid":false,"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-6214","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-5579","authenticated-orcid":false,"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7151-4311","authenticated-orcid":false,"given":"Rosirene","family":"Paczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"3055_CR1","unstructured":"National Heart, Lung, and Blood Institute COPD: what is COPD? 2023. https:\/\/www.nhlbi.nih.gov\/health\/copd. Accessed 30 May 2024."},{"key":"3055_CR2","unstructured":"Global Initiative for Chronic Obstruction Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2024 report. 2024. https:\/\/goldcopd.org\/2024-gold-report\/. Accessed 8 Mar 2024."},{"key":"3055_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40266-023-01038-0","volume":"40","author":"MG Matera","year":"2023","unstructured":"Matera MG, Hanania NA, Maniscalco M, Cazzola M. Pharmacotherapies in older adults with COPD: challenges and opportunities. Drugs Aging. 2023;40:605\u201319.","journal-title":"Drugs Aging"},{"key":"3055_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1465-9921-14-109","volume":"14","author":"J Bryant","year":"2013","unstructured":"Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2013;14:109.","journal-title":"Respir Res"},{"key":"3055_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","volume":"162","author":"B Alc\u00e1zar-Navarrete","year":"2022","unstructured":"Alc\u00e1zar-Navarrete B, Jamart L, S\u00e1nchez-Covisa J, Ju\u00e1rez M, Graefenhain R, Sicras-Mainar A. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. Chest. 2022;162:1017\u201329.","journal-title":"Chest"},{"key":"3055_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","volume":"105","author":"EL Toy","year":"2011","unstructured":"Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435\u201341.","journal-title":"Respir Med"},{"key":"3055_CR7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","volume":"107","author":"MJ M\u00e4kel\u00e4","year":"2013","unstructured":"M\u00e4kel\u00e4 MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107:1481\u201390.","journal-title":"Respir Med"},{"key":"3055_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/thx.2007.086041","volume":"63","author":"J Bourbeau","year":"2008","unstructured":"Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831\u20138.","journal-title":"Thorax"},{"key":"3055_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106807","volume":"197","author":"D Mannino","year":"2022","unstructured":"Mannino D, Bogart M, Wu B, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study. Respir Med. 2022;197:106807.","journal-title":"Respir Med"},{"key":"3055_CR10","doi-asserted-by":"publisher","first-page":"1147985","DOI":"10.3389\/fphar.2023.1147985","volume":"14","author":"L Lin","year":"2023","unstructured":"Lin L, Liu C, Cheng W, et al. Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: a prospective observational study in China. Front Pharmacol. 2023;14:1147985.","journal-title":"Front Pharmacol"},{"key":"3055_CR11","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.2147\/COPD.S370540","volume":"17","author":"DMG Halpin","year":"2022","unstructured":"Halpin DMG, Rothnie KJ, Banks V, et al. Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting. Int J Chron Obstruct Pulmon Dis. 2022;17:2417\u201329.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3055_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/PPA.S209532","volume":"13","author":"M George","year":"2019","unstructured":"George M, Bender B. New insights to improve treatment adherence in asthma and COPD. Patient Prefer Adher. 2019;13:1325\u201334.","journal-title":"Patient Prefer Adher"},{"key":"3055_CR13","unstructured":"Medicare.gov. What's medicare? 2024. https:\/\/www.medicare.gov\/what-medicare-covers\/your-medicare-coverage-choices\/whats-medicare. Accessed 14 Mar 2024."},{"key":"3055_CR14","doi-asserted-by":"publisher","first-page":"469580221121511","DOI":"10.1177\/00469580221121511","volume":"59","author":"B Tang","year":"2022","unstructured":"Tang B, Li Z, Hu S, Xiong J. Economic implications of health care burden for elderly population. Inquiry. 2022;59:469580221121511.","journal-title":"Inquiry"},{"key":"3055_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/agm2.12045","volume":"1","author":"A Smaje","year":"2018","unstructured":"Smaje A, Weston-Clark M, Raj R, Orlu M, Davis D, Rawle M. Factors associated with medication adherence in older patients: a systematic review. Aging Med (Milton). 2018;1:254\u201366.","journal-title":"Aging Med (Milton)"},{"key":"3055_CR16","unstructured":"FDA. Highlights of prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209482s000lbl.pdf. Accessed 14 Mar 2024."},{"key":"3055_CR17","unstructured":"FDA. Highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212122s000lbl.pdf. Accessed 14 Mar 2024."},{"key":"3055_CR18","unstructured":"IQVIA. Available IQVIA Data. 2024. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/available-iqvia-data. Accessed 07 Aug 2024."},{"key":"3055_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/COPD.S184653","volume":"14","author":"M Bogart","year":"2019","unstructured":"Bogart M, Stanford RH, Lalibert\u00e9 F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343\u201352.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3055_CR20","first-page":"117","volume":"92","author":"LA Anghel","year":"2019","unstructured":"Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92:117\u201322.","journal-title":"Med Pharm Rep"},{"key":"3055_CR21","first-page":"198","volume":"27","author":"LGS Bengtson","year":"2021","unstructured":"Bengtson LGS, Bancroft T, Schilling C, Buikema AR, Stanford RH. Development and validation of a drug adherence index for COPD. J Manag Care Spec Pharm. 2021;27:198\u2013209.","journal-title":"J Manag Care Spec Pharm"},{"key":"3055_CR22","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2147\/COPD.S259850","volume":"15","author":"C Moretz","year":"2020","unstructured":"Moretz C, Cole AL, Mu G, et al. Evaluation of medication adherence and rescue medication use in non-exacerbating patients with COPD receiving umeclidinium\/vilanterol or budesonide\/formoterol as initial maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2020;15:2207\u201315.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3055_CR23","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"3055_CR24","unstructured":"Elixhauser A, Steiner C, Kruzikas D. Agency for Healthcare Research and Quality. HCUP Comorbidity Software. Healthcare Cost and Utilization Project (HCUP). 2015. https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp#download. Accessed 20 May\u00a02024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03055-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03055-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03055-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:53:33Z","timestamp":1738407213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03055-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3055"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03055-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Corinne Young is an employee of the Association of Pulmonary Advanced Practice Providers and Clinical Services. Lydia Y. Lee was a university worker hired by GSK at the time of this study. Lydia Y. Lee is currently an employee of Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA (Boehringer Ingelheim has no connection to this study). Kristi K. DiRocco, Stephen G. Noorduyn, and Rosirene Paczkowski are employees of GSK and hold financial equities in GSK. Stephen G. Noorduyn is also a PhD candidate at McMaster University, Hamilton, ON, Canada. Guillaume Germain, Jacob Klimek, Fran\u00e7ois Lalibert\u00e9, and Dominique Lejeune are employees of Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada, which received funding from GSK to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data reported in this publication are contained in a database owned by IQVIA and contain proprietary elements. Therefore, these data cannot be broadly disclosed or made publicly available at this time. The disclosure of this data to third-party clients assumes certain data security and privacy protocols are in place and that the third-party client has executed IQVIA\u2019s standard license agreement, which includes restrictive covenants governing the use of the data. Permission was obtained from IQVIA to use the data. This study complied with all applicable laws regarding subject privacy. No direct subject contact or primary collection of individual human subject data occurred in this study. This study used existing, fully de-identified data that complied with the requirements of the Health Insurance Portability and Accountability Act, and the subject(s) cannot be identified, directly or through identifiers. The study results are in tabular form and aggregate analyses that omit subject identification. As per Title\u00a045 of CFR, Part\u00a046 (), informed consent, ethics committee, or institutional review board review were not needed, as the claims data analysis of our study was a retrospective analysis of existing data (hence no patient intervention or interaction), and no patient-identifiable information was included in the claims dataset.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}